Neuphoria Therapeutics Inc. Receives Nasdaq Compliance Extension

Neuphoria Therapeutics Inc. (the 'Company') received a deficiency notification letter from Nasdaq on July 18, 2025, for failing to hold an annual general meeting of stockholders within twelve months of the end of its fiscal year ended June 30, 2024. The Company submitted a plan to regain compliance, which Nasdaq accepted on September 10, 2025, granting an extension of 180 calendar days until December 29, 2025. The Company intends to file its annual report on Form 10-K by September 29, 2025, and hold its annual shareholder meeting within the compliance period. The filing includes forward-looking statements about the Company's ability to maintain its Nasdaq listing and other risks.